Focus:
Cardiovascular
-
23 April 2019 pressreleases
Creative Pharma Services Attended Hellenic Society for Pharmaceutical Management
Creative Pharma Services attended the Hellenic Society for Pharmaceutical Management on 18 April.
-
5 April 2019 whitepapers
The Odour of Blood
Blood is an extremely complex mixture and the number of different components that can be detected in its aroma owes as much to the separating ability and sensitivity of the...
-
27 March 2019 Comment
HeartMate 3 pump technology passes with flying colours
Abbott’s MagLev pump technology is thought to be responsible for the reduction of many severe complications of end-stage heart failure treatment.
-
25 March 2019 Comment
Paclitaxel-coated devices under close watch by FDA following long-term, follow-up data
Minimally invasive interventions for treating peripheral artery disease (PAD) are growing as they continue to demonstrate better patient outcomes compared to pharmaceutical treatment and open surgery.
-
14 March 2019 News
Stanford researchers identify existing drug can mitigate chemotherapy side effects
Researchers from the Stanford University School of Medicine have discovered that AMPK activators, which include metformin for type 2 diabetes, could mitigate the cardiac side effects of chemotherapy drug trastuzumab.
-
13 March 2019 Comment
Top drivers behind cardiovascular market growth by 2024
Only two pipeline agents in the cardiovascular space are expected to reach blockbuster status (with sales over $1 billion) by 2024.
-
4 March 2019 News
FDA announces another carcinogenic impurity in ARB blood pressure drugs
The US Food and Drug Administration (FDA) has revealed that a third impurity has been found in generic angiotensin II receptor blocker (ARB) drugs indicated for blood pressure and heart...
-
28 February 2019 News
Novartis and Blackstone Life launch new firm Anthos Therapeutics
Novartis and private investment platform Blackstone Life Sciences have launched a new biopharmaceutical company Anthos Therapeutics focused on targeted therapies for cardiovascular diseases.
-
25 February 2019 Digital Disruption
Novartis exercises rights to Ionis’ CV drug TQJ230
Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy, from Akcea Therapeutics’ affiliate Ionis...
-
25 February 2019 News
AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patients
Global pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse cardiovascular events, in the...